Acelyrin (SLRN) Stock Price, News & Analysis

Company Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Key Stats

• Today's Range: $2.27 to $2.27
• 50-Day Range: $2.05 to $2.48
• 52-Week Range: $1.85 to $7.10
• Volume: N/A
• Average Volume: 1.29 million shs
• Market Capitalization: $229.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.33
• Consensus Rating: Hold

SLRN Stock Analysis - Frequently Asked Questions

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) announced its earnings results on Wednesday, May, 14th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.40.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an initial public offering (IPO) on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share.

Who are Acelyrin's major shareholders?

Acelyrin's top institutional investors include Group One Trading LLC. Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Mina Kim, Daniel J Becker and Ronald Oyston.
View institutional ownership trends.

What other stocks do shareholders of Acelyrin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acelyrin investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 9/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLRN
• CIK: 1962918
• Web: www.acelyrin.com
• Phone: 805-730-0360
• Fax: N/A
• Employees: 135
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Acelyrin: $7.33
• High Price Target: $13.00
• Low Price Target: $3.00
• Potential Upside/Downside: +223.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$381.64 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.12%
• Return on Assets: -39.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.15
• Quick Ratio: 7.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.74 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 100,954,000
• Free Float: 86,682,000
• Market Cap: $229.17 million
• Optionable: Optionable
• Beta: 1.07